Table 1

Clinical profile of patients followed at start of study
Pt
 Age (yrs)
 Wt (kg)
 FEV1 (%)
 % HbA1c at Dx
 Rx Course (yrs)
 Clinical Data
I1
 28
 65.8
 56
 5.5
 4
 PI, LupusN, Deceased
I2
 31
 65.3
 44
 14.3
 2
 PI, Deceased
I3
 13
 41.9
 57
 9.3
 4
 PS
I4
 33
 54.3
 18
 10.0
 2
 PI, Deceased, RI*
I5
 14
 49.0
 99
 10.9
 8
 PI
I6
 44
 81.5
 30
 9.2
 5
 PI, Cor P, HTN, BPH
I7
 24
 53.0
 57
 7.3
 3
 PI, AIHS, RI
I8
 21
 70.5
 93
 9.8
 10
 PI







S1
 29
 75.5
 71
 7.1
 1
 PI
S2
 17
 33.6
 33
 8.1
 2
 PI, Deceased
S3
 25
 73.9
 48
 7.8
 4
 PI, Deceased
S4
 33
 97.5
 83
 6.3
 1
 PI, Bipolar, HTN
S5
 18
 49.7
 30
 6.6
 1
 PI, Deceased







M1I4
 35
 51.5
 17
 9.7
 1
 PI
M2
 24
 71.1
 117
 5.4
 2
 PI
M3I5
 22
 68.5
 68
 9.6
 2
 PI
M4
 19
 70.0
 100
 6.1
 3
 PI
M5
 22
 67.7
 88
 13.3
 3
 PI, Hepatic Cirrhosis
M6
 15
 41.8
 85
 8.9
 5
 PI







T1
 29
 58.0
 47
 13.3
 2
 PI
T2
 20
 44.4
 23
 5.1
 1
 PI
T3I6
 49
 85.5
 29
 9.2
 2
 PI, Cor P, HTN, BPH
T4I7
 32
 55.7
 65
 7.3
 2
 PI, AIHS, RI
T5S4
 34
 96.5
 92
 6.3
 1
 PI, Bipolar, HTN
T6
 40
 54.0
 56
 9.6
 2
 PI, Lupus, RI ABPA

Pt, patient (subscripts identify patient number, e.g. M1I4 was the first patient started on metformin and the fourth patient started on insulin); Rx Course (Yrs), represents the number of years that a patient received consecutive therapy with a specific class of agent; Mon, months; I, insulin; S, sulfonylurea; M, metformin; T, thiazolidinediones, FEV1, forced expiratory volume at 1 second; HbA1c, percent glycosylated hemoglobin; PI, pancreatic insufficient; PS, pancreatic sufficient; LupusN, lupus with nephritis; RI, renal insufficiency; Cor P, cor pulmonale; HTN, hypertension; BPH, benign prostatic hypertrophy; AIHS, autoimmune hypersplenism; ABPS, allergic bronchopulmonary aspergillosis. *Patient was switched back to insulin when diagnosed with renal insufficiency.

Onady and Langdon BMC Endocrine Disorders 2006 6:4   doi:10.1186/1472-6823-6-4